Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gentian Diagnostics ASOSL:GENT 68 EV-to-EBIT is 1,692.32 as of Aug. 12, 2026. GuruFocus rates OSL:GENT with a GF Score™ of 68/100 and a GF Value™ of kr59.45 (Significantly Undervalued). Among 472 Medical Devices & Instruments companies, Gentian Diagnostics AS ranks worse than 99.36% on this metric.
The historical rank and industry rank for Gentian Diagnostics AS's EV-to-EBIT or its related term are showing as below:
OSL:GENT'
s EV-to-EBIT Range Over the Past 10 Years
Min: -371.71 Med: -33.73 Max: 1701.6
Current: 1692.31
During the past 13 years, the highest EV-to-EBIT of Gentian Diagnostics AS was 1701.60. The lowest was -371.71. And the median was -33.73.
OSL:GENT's EV-to-EBIT is ranked worse than 99.36% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 19.215
vs OSL:GENT: 1692.31
Gentian Diagnostics AS (OSL:GENT) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Gentian Diagnostics AS's Enterprise Value for the quarter that ended in Jun. 2026 was kr523.4 Mil.
Gentian Diagnostics AS's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Gentian Diagnostics AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gentian Diagnostics AS EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Gentian Diagnostics AS's EV-to-EBIT falls into.
Gentian Diagnostics AS's current Enterprise Value is kr563.5 Mil.
Gentian Diagnostics AS's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gentian Diagnostics AS (OSL:GENT) has a EV-to-EBIT of 1,692.32 as of Aug. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Gentian Diagnostics AS and its competitors. According to the industry distribution chart, Gentian Diagnostics AS ranks #469 out of 472 companies in the Medical Devices & Instruments industry, placing it in the top 99.4%.
Is Gentian Diagnostics AS's EV-to-EBIT too high?
Gentian Diagnostics AS's current EV-to-EBIT is 1,692.32. The Medical Devices & Instruments industry median EV-to-EBIT is 19.22. Gentian Diagnostics AS's value of 1,692.32 is 8707.3% above this industry median. Based on the distribution chart, Gentian Diagnostics AS ranks #469 out of 472 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Gentian Diagnostics AS has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gentian Diagnostics AS ranks #469 out of 472 companies for EV-to-EBIT. This places Gentian Diagnostics AS in the lower half of its industry. The industry median EV-to-EBIT is 19.22. Gentian Diagnostics AS's value of 1,692.32 is 8707.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.22, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gentian Diagnostics AS's current EV-to-EBIT of 1,692.32 is 8707.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Gentian Diagnostics AS and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gentian Diagnostics AS's current EV-to-EBIT is 1,692.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (OSL:GENT) is currently considered Significantly Undervalued. The stock's GF Value™ is kr59.45, compared to a current price of kr40.50 — trading 31.9% below its estimated fair value. The current EV-to-EBIT is 1,692.32 and 8707.3% above the Medical Devices & Instruments industry median of 19.22. Gentian Diagnostics AS's overall GF Score™ is 68/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Gentian Diagnostics AS (OSL:GENT), the current EV-to-EBIT is 1,692.32 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?
Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued.
The current stock price of kr40.50 is trading 31.9% below its estimated GF Value™ of kr59.45.
GuruFocus considers Gentian Diagnostics AS to be Significantly Undervalued.
Key valuation signals for OSL:GENT:
EV-to-EBIT: 1,692.32
GF Value™: kr59.45 vs. price of kr40.50 (31.9% below fair value)
Industry Position: 8707.3% above the Medical Devices & Instruments median (#469 of 472)
No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
68GF Score
Get the complete analysis for OSL:GENT
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:GENT has been successfully added to your 
